Genmab As Stock Performance
| GMAB Stock | USD 30.43 1.06 3.37% |
The company retains a Market Volatility (i.e., Beta) of 0.95, which attests to possible diversification benefits within a given portfolio. Genmab AS returns are very sensitive to returns on the market. As the market goes up or down, Genmab AS is expected to follow. At this point, Genmab AS has a negative expected return of -0.0657%. Please make sure to check out Genmab AS's maximum drawdown, semi variance, and the relationship between the sortino ratio and potential upside , to decide if Genmab AS performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Genmab AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Genmab AS is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (3.17) | Five Day Return (7.14) | Year To Date Return 49.95 | Ten Year Return 134.13 | All Time Return 735.28 |
Last Split Factor 5:1 | Last Split Date 2018-05-01 |
1 | Genmab falls -6.5 percent GMAB | 10/20/2025 |
2 | Research Analysts Issue Forecasts for Genmab AS Q4 Earnings | 11/10/2025 |
3 | Transactions with shares and linked securities in Genmab AS made by managerial employees and their closely associated persons | 11/19/2025 |
4 | Genmab AS Stock Rating Upgraded by Wall Street Zen | 11/24/2025 |
5 | Transactions With Shares and Linked Securities in Genmab AS Made by Managerial Employees and Their Closely Associated Persons | 12/01/2025 |
6 | Bristol Myers Cancer Breakthrough Breyanzi Just Won Its Fifth FDA Approval | 12/05/2025 |
7 | Genmab Announces New Data from Phase 1b2 EPCORE CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transfor... | 12/08/2025 |
8 | Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period | 12/12/2025 |
9 | Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit 13B by 2030 | 12/19/2025 |
10 | Genmab ends development of late-stage oncology asset acasunlimab | 12/29/2025 |
| Begin Period Cash Flow | 14.9 B | |
| Total Cashflows From Investing Activities | -9.9 B |
Genmab AS Relative Risk vs. Return Landscape
If you would invest 3,212 in Genmab AS on October 2, 2025 and sell it today you would lose (169.00) from holding Genmab AS or give up 5.26% of portfolio value over 90 days. Genmab AS is currently does not generate positive expected returns and assumes 2.0049% risk (volatility on return distribution) over the 90 days horizon. In different words, 17% of stocks are less volatile than Genmab, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Genmab AS Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Genmab AS's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Genmab AS, and traders can use it to determine the average amount a Genmab AS's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0328
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GMAB |
Based on monthly moving average Genmab AS is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Genmab AS by adding Genmab AS to a well-diversified portfolio.
Genmab AS Fundamentals Growth
Genmab Stock prices reflect investors' perceptions of the future prospects and financial health of Genmab AS, and Genmab AS fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genmab Stock performance.
| Return On Equity | 0.29 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.41 % | ||||
| Operating Margin | 0.45 % | ||||
| Current Valuation | 17.36 B | ||||
| Shares Outstanding | 615.99 M | ||||
| Price To Earning | 66.53 X | ||||
| Price To Book | 3.48 X | ||||
| Price To Sales | 5.24 X | ||||
| Revenue | 21.53 B | ||||
| Gross Profit | 3.63 B | ||||
| EBITDA | 9.7 B | ||||
| Net Income | 7.84 B | ||||
| Cash And Equivalents | 21.61 B | ||||
| Cash Per Share | 33.05 X | ||||
| Total Debt | 1.03 B | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 13.11 X | ||||
| Book Value Per Share | 93.41 X | ||||
| Cash Flow From Operations | 7.77 B | ||||
| Earnings Per Share | 2.28 X | ||||
| Market Capitalization | 20.16 B | ||||
| Total Asset | 45.81 B | ||||
| Retained Earnings | 23.55 B | ||||
| Working Capital | 22.55 B | ||||
| Current Asset | 12.65 B | ||||
| Current Liabilities | 823.51 M | ||||
About Genmab AS Performance
By analyzing Genmab AS's fundamental ratios, stakeholders can gain valuable insights into Genmab AS's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Genmab AS has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Genmab AS has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 22.97 | 21.83 | |
| Return On Tangible Assets | 0.25 | 0.27 | |
| Return On Capital Employed | 0.17 | 0.17 | |
| Return On Assets | 0.17 | 0.18 | |
| Return On Equity | 0.21 | 0.22 |
Things to note about Genmab AS performance evaluation
Checking the ongoing alerts about Genmab AS for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Genmab AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Genmab AS generated a negative expected return over the last 90 days | |
| Genmab AS is unlikely to experience financial distress in the next 2 years | |
| Genmab AS has a strong financial position based on the latest SEC filings | |
| Latest headline from seekingalpha.com: Genmab ends development of late-stage oncology asset acasunlimab |
- Analyzing Genmab AS's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genmab AS's stock is overvalued or undervalued compared to its peers.
- Examining Genmab AS's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Genmab AS's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genmab AS's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Genmab AS's stock. These opinions can provide insight into Genmab AS's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |